The versatile heparin in COVID-19

Journal of Thrombosis and Haemostasis

Volumn 18, Issue 5, 2020, Pages 1020-1022

  Thachil, Jecko ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

D DIMER; HEPARIN; HISTONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW MOLECULAR WEIGHT HEPARIN; MITOGEN ACTIVATED PROTEIN KINASE; OXYGEN; PLASMINOGEN ACTIVATOR; THROMBIN; THROMBOPLASTIN; ANTICOAGULANT AGENT;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; BLOOD CLOTTING DISORDER; CORONAVIRUS DISEASE 2019; DRUG USE; ENDOTHELIAL DYSFUNCTION; FIBRINOLYSIS; HISTONE METHYLATION; HUMAN; INDIVIDUALIZATION; ITALY; LUNG EMBOLISM; LUNG GAS EXCHANGE; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MORTALITY; MORTALITY RISK; NONHUMAN; NOTE; OXYGEN TENSION; PNEUMONIA; PRIORITY JOURNAL; RISK REDUCTION; SEPSIS; TREATMENT OUTCOME; BETACORONAVIRUS; CORONAVIRINAE; CORONAVIRUS INFECTION; PANDEMIC; VIRUS PNEUMONIA;

ANTICOAGULANTS; BETACORONAVIRUS; CORONAVIRUS; CORONAVIRUS INFECTIONS; HEPARIN; HUMANS; PANDEMICS; PNEUMONIA, VIRAL;

EID: 85083223752     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.14821     Document Type: Note

References (27)

1. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-847.
2. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-1099.
3. Iba T, Nisio MD, Levy JH, Kitamura N, Thachil J. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open. 2017;7(9):e017046.
4. Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020. pii: ehaa231.
5. Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med. 2003;31(4 Suppl):S213-S220.
6. Gaertner F, Massberg S. Blood coagulation in immunothrombosis-At the frontline of intravascular immunity. Semin Immunol. 2016;28(6):561-569.
7. Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res. 2008;122(6):743-752.
8. Li JP, Vlodavsky I. Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb Haemost. 2009;102(5):823-828.
9. Esmon CT. Targeting factor Xa and thrombin: impact on coagulation and beyond. Thromb Haemost. 2014;111(4):625-633.
10. Poterucha TJ, Libby P, Goldhaber SZ. More than an anticoagulant: Do heparins have direct anti-inflammatory effects? Thromb Haemost. 2017;117(3):437-444.
11. Mousavi S, Moradi M, Khorshidahmad T, Motamedi M. Anti-inflammatory effects of heparin and its derivatives: a systematic review. Adv Pharmacol Sci. 2015;2015:507151.
12. Ozolina A, Sarkele M, Sabelnikovs O, et al. Activation of coagulation and fibrinolysis in acute respiratory distress syndrome: a prospective pilot study. Front Med. 2016;3:64.
13. Glas GJ, Van Der Sluijs KF, Schultz MJ, Hofstra JJ, Van Der Poll T, Levi M. Bronchoalveolar hemostasis in lung injury and acute respiratory distress syndrome. J Thromb Haemost. 2013;11(1):17-25.
14. Li J, Li Y, Yang B, Wang H, Li L. Low-molecular-weight heparin treatment for acute lung injury/acute respiratory distress syndrome: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2018;11(2):414-422.
15. Hanify JM, Dupree LH, Johnson DW, Ferreira JA. Failure of chemical thromboprophylaxis in critically ill medical and surgical patients with sepsis. J Crit Care. 2017;37:206-210.
16. Camprubí-Rimblas M, Tantinyà N, Guillamat-Prats R, et al. Effects of nebulized antithrombin and heparin on inflammatory and coagulation alterations in an acute lung injury model in rats. J Thromb Haemost. 2020;18(3):571-583.
17. Xu J, Zhang X, Pelayo R, et al. Extracellular histones are major mediators of death in sepsis. Nat Med. 2009;15(11):1318-1321.
18. Iba T, Hashiguchi N, Nagaoka I, Tabe Y, Kadota K, Sato K. Heparins attenuated histone-mediated cytotoxicity in vitro and improved the survival in a rat model of histone-induced organ dysfunction. Intensive Care Med Exp. 2015;3(1):36.
19. Zhu C, Liang Y, Li X, Chen N, Ma X. Unfractionated heparin attenuates histone-mediated cytotoxicity in vitro and prevents intestinal microcirculatory dysfunction in histone-infused rats. J Trauma Acute Care Surg. 2019;87(3):614-622.
20. Liu Y, Mu S, Li X, Liang Y, Wang L, Ma X. Unfractionated heparin alleviates sepsis-induced acute lung injury by protecting tight junctions. J Surg Res. 2019;238:175-185.
21. Ma J, Bai J. Protective effects of heparin on endothelial cells in sepsis. Int J Clin Exp Med. 2015;8(4):5547-5552.
22. Wojnicz R, Nowak J, Szyguła-Jurkiewicz B, et al. Adjunctive therapy with low-molecular-weight heparin in patients with chronic heart failure secondary to dilated cardiomyopathy: one-year follow-up results of the randomized trial. Am Heart J. 2006;152(4):713.e1-719.e7.
23. Frizelle S, Schwarz J, Huber SA, Leslie K. Evaluation of the effects of low molecular weight heparin on inflammation and collagen deposition in chronic coxsackievirus B3-induced myocarditis in A/J mice. Am J Pathol. 1992;141(1):203.
24. Shukla D, Spear PG. Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry. J Clin Invest. 2001;108(4):503-510.
25. Ghezzi S, Cooper L, Rubio A, et al. Heparin prevents Zika virus induced-cytopathic effects in human neural progenitor cells. Antiviral Res. 2017;140:13-17.
26. Vicenzi E, Canducci F, Pinna D, et al. Coronaviridae and SARS-associated coronavirus strain HSR1. Emerg Infect Dis. 2004;10(3):413-418.
27. https://www.biorxiv.org/content/10.1101/2020.02.29.971093v1.full